Nektar Therapeutics (NKTR): Price and Financial Metrics

Nektar Therapeutics (NKTR)

Today's Latest Price: $17.61 USD

0.42 (-2.33%)

Updated Sep 25 4:00pm

Add NKTR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

NKTR Stock Summary

  • Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; only 8.83% of US stocks have a lower such ratio.
  • NKTR's price/sales ratio is 19.39; that's higher than the P/S ratio of 92.54% of US stocks.
  • With a year-over-year growth in debt of -54.74%, Nektar Therapeutics's debt growth rate surpasses only 4.94% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Nektar Therapeutics are CLLS, ZYME, RGNX, PRQR, and APTX.
  • NKTR's SEC filings can be seen here. And to visit Nektar Therapeutics's official web site, go to
NKTR Daily Price Range
NKTR 52-Week Price Range

NKTR Stock Price Chart Technical Analysis Charts

NKTR Price/Volume Stats

Current price $17.61 52-week high $28.60
Prev. close $18.03 52-week low $13.63
Day low $17.48 Volume 1,336,105
Day high $18.16 Avg. volume 1,440,606
50-day MA $20.56 Dividend yield N/A
200-day MA $20.91 Market Cap 3.15B

Nektar Therapeutics (NKTR) Company Bio

Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.

NKTR Latest News Stream

Event/Time News Detail
Loading, please wait...

NKTR Latest Social Stream

Loading social stream, please wait...

View Full NKTR Social Stream

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Analyst Report: Nektar Therapeutics

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Yahoo | September 24, 2020

Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 5, 2020

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 6, 2020

Nektar Therapeutics Reports Second Quarter 2020 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.

Yahoo | August 6, 2020

If You Had Bought Nektar Therapeutics (NASDAQ:NKTR) Stock Five Years Ago, You Could Pocket A 106% Gain Today

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

Yahoo | August 5, 2020

Read More 'NKTR' Stories Here

NKTR Price Returns

1-mo -8.14%
3-mo -20.14%
6-mo -2.49%
1-year -1.62%
3-year -23.77%
5-year 56.81%
YTD -18.42%
2019 -34.33%
2018 -44.96%
2017 386.72%
2016 -27.18%
2015 8.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7239 seconds.